U.S. pharmaceutical company Johnson & Johnson (J&J)’s profits in the second quarter jumped 73 percent due to a surge in sales of medical equipment and diagnostic components as the Pandemic crisis calmed down.
J&J, the world’s largest health care product company, announced its quarterly net profit of 6.28 billion dollars on the 21st. The figure is equivalent to $2.53 per share, up sharply from $3.63 billion a year earlier.
Sales totaled 23.31 billion dollars, up 27.1 percent from a year earlier. Based in Brunswick, New Jersey, the pharmaceutical company said its overseas sales rose 29.5 percent to $11.39 billion. U.S. domestic sales rose 24.9 percent to $11.92 billion.
The sales surge sector, which has been stagnant in the Pandemic emergency, surged 62.7% to 6.98 billion dollars.
Sales of prescription drugs, known for their anti-cancer drugs Darzalex and Imbruvica, rose 17.2 percent to $12.6 billion.
Sales of general consumer health products such as Johnson & Johnson’s Tylenol and Band Aid rose 13.3% to $3.74 billion due to the coronavirus.
J&J said its annual net income is expected to range from $9.60 to $9.70 per share. Earlier in April, the forecast was up to $9.52. Its sales forecast also increased from up to 91.6 billion dollars to 94.6 billion dollars.